Fox Chase Cancer Center: Lymphoma trials
The registry lists 12 Lymphoma studies with Fox Chase Cancer Center as lead sponsor. 1 are open to participants now and 2 have results posted.
Early Phase 1 1Phase 1 4Phase 2 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingNCT06557330Phase 2
- Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin LymphomaTerminatedNCT02535247Phase 1/2Results posted
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT01169532Phase 1Results posted
- A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced CancerSuspendedNCT04827810Phase 1
- HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive LymphomaSuspendedNCT04668768Phase 2
- Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
- Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceCompletedNCT03311958Early Phase 1
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaWithdrawnNCT01539174Phase 2
- Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00062296Phase 2
- Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00021372Phase 2
- Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or LymphomaCompletedNCT00005021Phase 1
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00003957Phase 2